Gary Crocker Net Worth

The estimated Net Worth of Gary L Crocker is at least 2.71 百万$ dollars as of 10 August 2023. Mr. Crocker owns over 4,000 units of Merrimack Pharmaceuticals Inc stock worth over 2,013,879$ and over the last 13 years he sold MACK stock worth over 596,008$. In addition, he makes 95,258$ as Chairman of the Board、 President、 Treasurer at Merrimack Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Crocker MACK stock SEC Form 4 insiders trading

Gary has made over 46 trades of the Merrimack Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he bought 4,000 units of MACK stock worth 49,920$ on 10 August 2023.

The largest trade he's ever made was buying 207,000 units of Merrimack Pharmaceuticals Inc stock on 27 November 2013 worth over 770,040$. On average, Gary trades about 17,210 units every 69 days since 2012. As of 10 August 2023 he still owns at least 133,105 units of Merrimack Pharmaceuticals Inc stock.

You can see the complete history of Mr. Crocker stock trades at the bottom of the page.

Gary Crocker biography

Gary L. Crocker serves as Chairman of the Board, President, Treasurer of the Company. He has served as a member of our board of directors since 2004 and as Chairman of the Board since 2005. Mr. Crocker also served as our Interim President and Chief Executive Officer from October 2016 to February 2017. Since 2002, Mr. Crocker has served as President and Managing Director of Crocker Ventures, LLC, a privately-held life science investment firm funding differentiated biotechnology and medical device companies. Mr. Crocker has held senior executive positions or served on the board of directors of several life science companies, including as Chairman of the Board of ARUP Laboratories, co-founder and director of Theratech, Inc. (acquired by Actavis plc) and President, Chief Executive Officer and founder of Research Medical, Inc. (acquired by Baxter International). Mr. Crocker also served on the boards of directors of the publicly traded firms Interleuken Genetics, Inc. and The Med-Design Corporation. Mr. Crocker served as a member of the board of the Federal Reserve Branch of San Francisco from 1999 to 2007, and currently serves as the Chairman of the University of Utah’s Center for Medical Innovation and on the board of the Sorenson Legacy Foundation. Mr. Crocker holds an M.B.A. from Harvard Business School and a B.S. from Harvard College.

What is the salary of Gary Crocker?

As the Chairman of the Board、 President、 Treasurer of Merrimack Pharmaceuticals Inc, the total compensation of Gary Crocker at Merrimack Pharmaceuticals Inc is 95,258$. There are 1 executives at Merrimack Pharmaceuticals Inc getting paid more, with Ulrik Nielsen having the highest compensation of 1,317,610$.

How old is Gary Crocker?

Gary Crocker is 68, he's been the Chairman of the Board、 President、 Treasurer of Merrimack Pharmaceuticals Inc since 2019. There are 4 older and 7 younger executives at Merrimack Pharmaceuticals Inc. The oldest executive at Merrimack Pharmaceuticals Inc is Dr. Anthony J. Sinskey Ph.D., Sc.D., 81, who is the Co-Founder and Scientific Advisor.

What's Gary Crocker's mailing address?

Gary's mailing address filed with the SEC is C/O MERRIMACK PHARMACEUTICALS, INC., ONE BROADWAY 14TH FLOOR, CAMBRIDGE, MA, 02142.

Insiders trading at Merrimack Pharmaceuticals Inc

Over the last 13 years, insiders at Merrimack Pharmaceuticals Inc have traded over 1,152,598$ worth of Merrimack Pharmaceuticals Inc stock and bought 3,978,994 units worth 28,464,218$ . The most active insiders traders include Eric Western Standard Llcwe...、Robert J. Mulroy、Gary L Crocker. On average, Merrimack Pharmaceuticals Inc executives and independent directors trade stock every 18 days with the average trade being worth of 459,997$. The most recent stock trade was executed by Eric Western Standard Llcwe... on 26 December 2023, trading 49,550 units of MACK stock currently worth 651,583$.

What does Merrimack Pharmaceuticals Inc do?

merrimack is a fully integrated biopharmaceutical company that views cancer as a complex engineering challenge. through systems biology, which brings together the fields of biology, computing and engineering, merrimack aims to decrease uncertainty in drug development and clinical validation, and move discovery efforts beyond trial and error. such an approach has the potential to make individualized treatment of patients a reality. merrimack's first commercial product, onivydetm (irinotecan liposome injection), was approved by the u.s. fda on october 22, 2015. with four additional candidates in clinical studies, several in preclinical development and multiple biomarkers designed to support patient selection, merrimack is building one of the most robust oncology pipelines in the industry. for more information, please visit merrimack's website at www.merrimack.com or connect on twitter at @merrimackpharma.

Complete history of Mr. Crocker stock trades at Merrimack Pharmaceuticals Inc

Merrimack Pharmaceuticals Inc executives and stock owners

Merrimack Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Ulrik Nielsen,
  Independent Director
• Gary Crocker,
  Chairman of the Board, President, Treasurer
• Dr. Ulrik B. Nielsen,
  Co-Founder & Independent Director
• Gary L. Crocker M.B.A., MBA,
  Pres, Treasurer, Principal Financial Officer, Principal Accounting Officer, CEO & Chairman
• Tim Surgenor,
  IR Contact Officer
• Russell Ray,
  Independent Director
• Noah Levy,
  Independent Director
• Eric Andersen,
  Independent Director
• Timothy R. Surgenor,
  Sec.
• Dr. Daryl C. Drummond Ph.D.,
  Head of Research
• Dr. Fazal R. Khan Ph.D.,
  Sr. VP of Manufacturing
• Ellen K. Forest,
  Head of HR
• Geoffrey Grande C.F.A.,
  Sr. Director of Communications
• Dr. Anthony J. Sinskey Ph.D., Sc.D.,
  Co-Founder and Scientific Advisor
• Ana Radeljevic,
  
• Sergio L. Santillana,
  Chief Medical Officer
• John M. Dineen,
  Director
• Yasir B. Al Wakeel,
  CFO and Head of Corp Dev
• Jeffrey A Munsie,
  General Counsel
• James H. Quigley,
  Director
• John Mendelsohn,
  Director
• William A. Sullivan,
  CFO and Treasurer
• Edward J. Stewart,
  SVP & Pres, Healthcare Sol
• Peter N Laivins,
  Head of Development
• Michael E Porter,
  Director
• Richard Peters,
  President and CEO
• Robert J. Mulroy,
  President and CEO
• Birgit M. Schoeberl,
  Head of Discovery
• Vivian S Lee,
  Director
• William M. Mc Clements,
  Head of Corporate Operations
• George Demetri,
  Director
• Thomas E. Jr. Needham,
  Chief Business Officer
• Jean M. Franchi,
  Chief Financial Officer
• Capital Management, Llcjfl ...,
  
• Lp22 Nw Fund, Lp22 Nw Fund ...,
  
• Gordon J. Fehr,
  Director
• Anthony J Sinskey,
  Director
• James Van B. Dresser,
  Director
• Sarah E Nash,
  Director
• Fazal R. Khan,
  SVP of Manufacturing
• Robert C Gay,
  Director
• Walter M Phd Lovenberg,
  Director
• Clet M. Niyikiza,
  EVP of Development
• Jason Aryeh,
  10% owner